SYK and follicular lymphoma: TAK‐659, a novel SYK inhibitor, combined with R‐CHOP in patients with newly diagnosed high‐risk DLBCL including DLBCL transformed from follicular lymphoma and DEL, is well tolerated at a dose of 60 mg, with no requirement for dose modification.